NPM1 and acute myeloid leukemia: A 77-year-old woman with NPM1-mutated AML achieved CR after the third cycle of VEN/AZA therapy, and WT1 negativity was confirmed after the fifth cycle of VEN/AZA therapy with a 4-log reduction in its levels compared with the pre-treatment WT1 value.